Rationale for Adding BDC-1001 to Immune Checkpoint Inhibitor Therapy in HER2+ Breast Cancer
Ecaterina Ileana Dumbrava, MD, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.
Ecaterina Ileana Dumbrava, MD, an assistant professor in the Department of Investigational Cancer Therapeutics, of the Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.
BDC-1001 is currently being studied in an ongoing phase 1 study to determine, safety, durability and proper dosage. According to Dumbrava, synergistic activity was seen between the 2 agents in preclinical models. These preclinical model also had anti-PB1 activity and immunologic memory.
It was hypothesized that the activity observed preclinically may translate in human subjects. Researchers hope that the combination will lead to a durable and sustained responses.
FDA Grants Clearance for Phase 1 Trial of BL-M17D1 in Solid Tumors
November 11th 2024Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel antibody-drug conjugate BL-M17D1 in patients with advanced or metastatic solid tumors.
Read More
T-DXd Use in HER2+ Breast Cancer Influenced by Site of Metastases and AE Monitoring
October 21st 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO discussed recent updates from the DestinyBreast03 trial and other key data on treatment for HER2+ breast cancer in the first article of a 2-part series.
Read More
Wei Assesses Role of TROP2 and HER2 Status in Treatment With Sacituzumab for ER+ mBC
September 26th 2024During an in-person Community Case Forum in partnership with the Rocky Mountain Oncology Society, Mei Wei, MD, discussed data from the TROPiCS-02 trial of sacituzumab govitecan in patients with metastatic breast cancer.
Read More
